Compare Palantir Technologies Inc (PLTR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Palantir (PLTR) trades at $132.62, up 0.18% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.33 exceeding expectations. Revenue grew to $4.48 billion in 2025, and net income surged to $1.63 billion, reflecting robust profitability. Analyst sentiment is mixed, with a consensus price target of $185.75 and 46% of analysts rating it a Buy.

Outlook: PLTR's accelerating revenue growth and expanding margins support long-term upside, but high valuation multiples (P/E 151.52, P/S 66.33) pose risks if growth slows. Key catalysts include continued AI adoption and execution on guidance. Risks include competitive pressures and market volatility. The stock offers growth potential but requires tolerance for premium valuation and earnings sensitivity.

Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.

The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.